What should you know about an NGS panel for lung cancer?

An NGS panel for lung cancer examines many tumour gene changes at once to help identify treatment options. It can be performed on tumour tissue and, in some situations, on DNA from a blood sample. The report is one part of planning care; it does not by itself confirm how an individual will respond.

The laboratory searches for changes that may help classify the tumour or point toward a targeted medicine. It may also show that a different test is needed, that no actionable change was found, or that the sample was insufficient. Results are considered with the lung cancer subtype, stage, scan findings, symptoms, and previous treatment.

Genomic results can influence whether the team discusses targeted treatment, chemotherapy, radiotherapy, surgery, or supportive care. A panel does not replace imaging or examination, and a detected change does not guarantee that a matching treatment is suitable or available.

Ask whether the sample is tissue, blood, or both, and whether enough material is available. Tell your team about prior cancer treatments and medicines. When the report arrives, ask which findings are clinically meaningful now, whether repeat testing is useful after the cancer changes, and how the result fits your scan. Further information is available on [Lung Cancer](/conditions/lung-cancer/) and [Genomic Tumour Profiling](/treatments/diagnostics-and-staging/genomic-tumour-profiling/).

Do not wait for a genomic report if you have urgent symptoms. Seek immediate medical help for severe breathlessness, chest pain, coughing blood, new confusion, fainting, or sudden weakness. Contact your oncology team soon for worsening cough, a new hoarse voice, fever, or difficulty managing pain. A result may guide future planning, but symptoms still need prompt assessment.

Which genes or changes does this panel assess? Was the sample adequate? Could the result alter my treatment today? What happens if no actionable change is found? Should relatives be tested, or is this result limited to the tumour?